December 5, 2025Hematology

How to approach the high-risk myeloma from induction through relapse?

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis reveals improved outcomes in relapsing multiple myeloma through clinical trials and autologous stem cell transplantation.

Improved prognosis is achieved through early identification of minimal residual disease in patients.
Clinical trials support the use of autologous stem cell transplantation for high-risk multiple myeloma.
Chimeric antigen receptor T-cells are showing promise in treating relapsing multiple myeloma cases.
New treatment strategies aim to mitigate therapeutic challenges in high-risk multiple myeloma.

Christoph Schaefers (2025) studied this question.

View Full Paper

Ask AI

Bookmark